Yes — but with restrictions. Compounded semaglutide is still available through certain licensed telehealth providers in 2026, but the regulatory landscape changed significantly in 2025. The shortage-era free pass is over. What's available now depends on the type of compounding pharmacy, the state you're in, and the clinical justification for your prescription.
What happened in 2025
For most of 2022–2024, compounded semaglutide was widely available because the FDA listed brand-name semaglutide (Wegovy, Ozempic) as being in shortage. During a shortage, compounding pharmacies are legally permitted to produce copies of the medication to ensure patient access. That's what drove the explosion of telehealth GLP-1 programs.
In February 2025, the FDA declared the semaglutide shortage over — and with that declaration came deadlines for most compounding pharmacies to stop producing compounded semaglutide.
FDA declares semaglutide shortage resolved. The legal basis for most compounding pharmacies to produce compounded semaglutide is removed.
Deadline for state-licensed pharmacies and physicians to stop dispensing compounded semaglutide that is "essentially a copy" of an FDA-approved product.
Deadline for 503B outsourcing facilities — the larger compounding operations that supply many telehealth programs — to stop producing compounded injectable semaglutide.
Legal gray zone and enforcement questions. Many telehealth providers continued offering compounded semaglutide under various legal arguments. FDA enforcement has been uneven. The situation remains in flux.
What "essentially a copy" actually means
The FDA's restriction targets compounded semaglutide that is "essentially identical" to Wegovy or Ozempic — meaning it uses the same active ingredient in the same salt form (semaglutide base) with no meaningful clinical difference.
This is where it gets complicated. Many compounding pharmacies use semaglutide acetate or semaglutide sodium — salt forms that are chemically different from the semaglutide base used in Wegovy. Some providers and pharmacies have argued this means their products are not "essentially identical" and therefore not subject to the same restrictions.
The FDA does not consider semaglutide acetate or semaglutide sodium to be interchangeable with Wegovy's semaglutide base. The agency has stated these salt forms have not been evaluated for safety or efficacy. This is a genuine scientific and regulatory dispute — not a technicality — and it's worth understanding before starting or continuing a compounded program.
What this means if you're already on compounded semaglutide
If you started a compounded semaglutide program before the 2025 deadlines and have been continuing, you're in a situation that depends heavily on which provider and pharmacy you're using. Some providers exited the market entirely. Others restructured their programs around individual patient need justifications or switched to tirzepatide, which remains on the shortage list longer.
The providers I list on this site are still actively prescribing compounded semaglutide as of mid-2026. I can't guarantee that remains true indefinitely — the FDA situation is evolving and provider availability changes without notice. This is why verifying directly with any provider before starting (or continuing) a program matters more now than it did two years ago.
What about compounded tirzepatide?
Tirzepatide (the active ingredient in Zepbound and Mounjaro) has had a different trajectory. It remained on the FDA shortage list longer than semaglutide, which means the compounding window stayed open for tirzepatide programs into 2025 and 2026. Several providers shifted their focus toward tirzepatide as the semaglutide situation tightened.
As of mid-2026, compounded tirzepatide is more readily available than compounded semaglutide through licensed telehealth programs — though this too is subject to change as the FDA continues to update its shortage determinations.
Which providers are still prescribing compounded semaglutide
I track the providers I list specifically through the lens of what's available for long-term maintenance — not just first-time prescriptions. Several are still actively offering compounded semaglutide programs as of mid-2026. I put them side by side with current pricing, formats, and commitment terms so you can verify what's available before you commit to anything.
See which providers are still offering compounded GLP-1
Nine telehealth programs compared — what they prescribe, what format, current starting prices, and commitment terms. Updated regularly as the regulatory situation evolves.
See the comparison →The honest bottom line
Compounded semaglutide is still available in 2026 — but it operates in a more legally constrained environment than it did during the shortage years. The providers still offering it are doing so through specific legal pathways, and the situation can change on short notice if the FDA changes its enforcement approach.
If you're currently on a compounded program, the most important thing you can do is understand what pharmacy is filling your prescription, verify they are a licensed 503A pharmacy, and have a contingency plan if your current provider exits the market. The compounded GLP-1 space is not going away — but it's not as stable as it was two years ago either.
For people in the maintenance phase specifically — already at goal weight, on a lower stable dose — the regulatory uncertainty is worth thinking about when choosing a long-term provider. A program built around brand-name access (like MEDGm, which can prescribe Zepbound and Wegovy when clinically appropriate) gives you a fallback if the compounded landscape tightens further.